Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.59 · Revenue $183.57M · 5 analysts
Est. EPS $-0.14 · Revenue $195.76M · 4 analysts
Est. EPS $-2.35 · Revenue $715.30M · 5 analysts
Est. EPS $-0.28 · Revenue $196.90M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $451.4M | +146.7% | +7.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-66.4M | +42.5% | -166.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +93.2% | +0.2% | -1.2% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -15.7% | +76.1% | -203.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -14.7% | +76.7% | -148.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-22.3M | +73.6% | +305.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -4.9% | +89.3% | +291.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 27.3% | -15.5% | +0.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 3.85x | -12.9% | -14.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $562.2M | +49.1% | +5.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.59 vs -1.43 | -11.3% | -0.43 vs -1.59 | +72.9% |
| Revenue Surprise | $451.4M vs $444.1M | +1.6% | $173.9M vs $183.6M | -5.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Azamian Bobak R. | director, officer: President/CEO and Board Chair | Common Stock | D | 10,000 | $80.06 |
| Sep 2, 2026 | Lin Elizabeth Yeu | officer: Chief Medical Officer | Common Stock | D | 5,387 | $80.00 |
| Sep 2, 2026 | Lin Elizabeth Yeu | officer: Chief Medical Officer | Common Stock | D | 1,590 | $80.00 |
| Sep 1, 2026 | Lin Elizabeth Yeu | officer: Chief Medical Officer | Common Stock | D | 4,601 | $73.86 |
| Jun 25, 2026 | Goodrich Katherine | director | Stock Option (right to buy) | A | 3,837 | $64.34 |
Operator: Hello, and welcome to Tarsus Pharmaceuticals Second Quarter 2026 Financial Results Conference Call and announcement to acquire Alkeus Pharmaceuticals. As a reminder, this call is being recorded. [Operator Instructions] At this time, I would like to turn the call over to Sarah Nives, Investor Relations, to lead off the call. Sarah Nives: Thank you. Before we begin, I encourage everyone to visit the Investors section of the Tarsus website to view the press releases issued today and related materials we will be discussing today. Joining me on the call are Bobby Azamian, our Chief Executive Officer and Chairman; Neera Clase, our Interim Chief Commercial Officer; Sesha Neervannan, our Chief Operating Officer; and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer. And joining us for Q&A is Dr. Liz Yeu, our Chief Medical Officer. I'd like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I'll turn the call over to Bobby. Bobak Azamian: Hello, and thank you for joining us. Today is an important day for Tarsus. We're reporting another exceptional quarter for XDEMVY and announcing the acquisition of Alkeus Pharmaceuticals and gildeuretinol or ALK-001, a late-stage investigational therapy for Stargardt disease. When we launched XDEMVY, we believed Demodex blepharitis or DB was one of the largest diseases in eye care, hiding in plain sight. Our ambition was never simply to commercialize a single medicine. It was to demonstrate that by identifying diseases that have been overlooked for years, creating categories, developing medicines with the potential to redefine the standard of care and executing with excellence, we can fundamentally change patient care while building a leading eye care company. XDEMVY continues to prove that thesis. Nearly 3 years after launch, more than 700,000 patients have been treated. XDEMVY has generated almost $1 billion in net product sales reported to date, and we are well on our way to over $2 billion in potential annual peak sales. This quarter alone, XDEMVY generated approximately $174 million in net product sales, representing more than 69% year-over-year growth. XDEMVY has never been stronger, and we believe we are still in the early stages of realizing its full commercial opportunity. What's more, XDEMVY is powering innovation at Tarsus, and that's precisely why we have the confidence to make strategic investments like the one we are announcing today. We are investing in assets with novel disease-modifying approaches, compelling clinical evidence and a clear strategic fit to build a leading eye care company. ALK-001 is exactly that …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman | USD 1,318,208 | — | — | Active |
Jeffrey S. Farrow | Chief Financial Officer & Chief Strategy Officer | USD 888,645 | Male | 1962 | Active |
Seshadri Neervannan | Chief Operating Officer | USD 839,200 | — | 1968 | Active |
Aziz Mottiwala | Chief Commercial Officer | USD 821,650 | Male | 1978 | Active |
Bryan Wahl | General Counsel & Corporate Secretary | USD 771,233 | — | 1978 | Active |
Dianne C. Whitfield | Chief Human Resources Officer | USD 578,900 | Female | 1977 | Active |
Elizabeth Yeu | Chief Medical Officer | USD 156,691 | — | 1978 | Active |
Adrienne Kemp | Vice President of Corporate Communications | — | Female | — | Active |
Scott Youmans | Vice President of Sales | — | Male | — | Active |
Cara Miller | Senior Vice President of Corporate Affairs | — | Female | — | Active |
Neera Clase | Senior Vice President of Market Access | — | Female | — | Active |
David Nakasone | Head of Investor Relations | — | Male | — | Active |
Matthew Rossen | Vice President of Marketing | — | Male | 1978 | Active |
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th H.C.
CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug Designation for oral gildeuretinol for the treatment of Stargardt disease.
Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol, also known as ALK-001, to its pipeline.
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.48 per share a year ago.
